🔗 Share this article The Global Health Body Raises Concern Over Severe Scarcity of Weight-Loss Injections Less than one in 10 people eligible to benefit from obesity jabs including Wegovy are able to get them, caution the WHO as it issues its first advice on the therapies. With more than one billion individuals worldwide now classified as obese, it is advocating for increased and just availability to GLP-1 medication. According to forecasts, more than two billion could be obese by 2030 without intervention. "Our latest guidance affirms that excess weight is a long-term condition that can be addressed with thorough and ongoing support," said WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and supply-chain constraints are significant obstacles to broad access to the jabs that can assist patients in reducing substantial body mass, explains the body. GLP-1 Therapy Scarcity Even under the present most optimistic outlook, the production of these medications would only suffice for around 100 million people – less than 10% of the global need, according to the health organization. The recommendation encourages countries and companies to widen access, by approaches including licensing agreements. A patent on a key compound – the main ingredient of a leading brand – is due to expire in multiple nations in 2026. The Way Weight-Loss Drugs Operate GLP-1 drugs imitate a biological compound to slow digestion, curb appetite and boost the sense of being full so people eat less. Individuals commonly see weight reduction after several weeks of starting on the weekly injections. Research indicates patients may regain a significant portion within a year of discontinuing the medication, because their typical appetite come back. To be above a healthy weight elevates your likelihood for contracting diseases, including diabetes, heart disease, stroke, and certain cancers. Obesity affects people in every country and was associated with over three and a half million fatalities worldwide in 2024, according to the WHO.
Less than one in 10 people eligible to benefit from obesity jabs including Wegovy are able to get them, caution the WHO as it issues its first advice on the therapies. With more than one billion individuals worldwide now classified as obese, it is advocating for increased and just availability to GLP-1 medication. According to forecasts, more than two billion could be obese by 2030 without intervention. "Our latest guidance affirms that excess weight is a long-term condition that can be addressed with thorough and ongoing support," said WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and supply-chain constraints are significant obstacles to broad access to the jabs that can assist patients in reducing substantial body mass, explains the body. GLP-1 Therapy Scarcity Even under the present most optimistic outlook, the production of these medications would only suffice for around 100 million people – less than 10% of the global need, according to the health organization. The recommendation encourages countries and companies to widen access, by approaches including licensing agreements. A patent on a key compound – the main ingredient of a leading brand – is due to expire in multiple nations in 2026. The Way Weight-Loss Drugs Operate GLP-1 drugs imitate a biological compound to slow digestion, curb appetite and boost the sense of being full so people eat less. Individuals commonly see weight reduction after several weeks of starting on the weekly injections. Research indicates patients may regain a significant portion within a year of discontinuing the medication, because their typical appetite come back. To be above a healthy weight elevates your likelihood for contracting diseases, including diabetes, heart disease, stroke, and certain cancers. Obesity affects people in every country and was associated with over three and a half million fatalities worldwide in 2024, according to the WHO.